These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 6865653)

  • 1. Lithium attenuates dopamine depleting effects of reserpine and tetrabenazine but not that of alpha methyl-p-tyrosine.
    Reches A; Hassan MN; Jackson VR; Fahn S
    Life Sci; 1983 Jul; 33(2):157-60. PubMed ID: 6865653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of reserpine and tetrabenazine on rat striatal synaptosomal dopamine biosynthesis and synaptosomal dopamine pools.
    Kuczenski R
    J Pharmacol Exp Ther; 1977 May; 201(2):357-67. PubMed ID: 870679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pilocarpine-induced purposeless chewing behaviour in rats is dependent on intact central stores of 5-HT.
    Stewart B; Rose S; Jenner P; Marsden CD
    Eur J Pharmacol; 1987 Oct; 142(1):173-6. PubMed ID: 2961579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain.
    Reches A; Burke RE; Kuhn CM; Hassan MN; Jackson VR; Fahn S
    J Pharmacol Exp Ther; 1983 Jun; 225(3):515-21. PubMed ID: 6864517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the acute actions of amine-depleting drugs and dopamine receptor antagonists on dopamine function in the brain in rats.
    Hong M; Jenner P; Marsden CD
    Neuropharmacology; 1987; 26(2-3):237-45. PubMed ID: 2884588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of dopamine turnover by monitoring the decline of dopamine metabolites in rat CSF after alpha-methyl-p-tyrosine.
    Mignot E; Laude D
    J Neurochem; 1985 Nov; 45(5):1527-33. PubMed ID: 2864397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amphetamine-induced dopamine release in the rat striatum: an in vivo microdialysis study.
    Butcher SP; Fairbrother IS; Kelly JS; Arbuthnott GW
    J Neurochem; 1988 Feb; 50(2):346-55. PubMed ID: 2447237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of nonserotonergic [3H]ketanserin binding sites associated with nerve terminals in rat brain and with platelets; relation with release of biogenic amine metabolites induced by ketanserin- and tetrabenazine-like drugs.
    Leysen JE; Eens A; Gommeren W; van Gompel P; Wynants J; Janssen PA
    J Pharmacol Exp Ther; 1988 Jan; 244(1):310-21. PubMed ID: 3336007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lithium does not interact with haloperidol in the dopaminergic pathways of the rat brain.
    Reches A; Jackson-Lewis V; Fahn S
    Psychopharmacology (Berl); 1984; 82(4):330-4. PubMed ID: 6427824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulating role of lithium on dopamine turnover, prolactin release, and behavioral supersensitivity following haloperidol and reserpine.
    McIntyre IM; Kuhn C; Demitriou S; Fucek FR; Stanley M
    Psychopharmacology (Berl); 1983; 81(2):150-4. PubMed ID: 6415746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Striatal adenosine A(2A) receptor blockade increases extracellular dopamine release following l-DOPA administration in intact and dopamine-denervated rats.
    Gołembiowska K; Dziubina A
    Neuropharmacology; 2004 Sep; 47(3):414-26. PubMed ID: 15275831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subchronic methamphetamine treatment enhances ouabain-induced striatal dopamine efflux in vivo.
    Kanzaki A; Akiyama K; Otsuki S
    Brain Res; 1992 Jan; 569(2):181-8. PubMed ID: 1371707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phencyclidine-induced inhibition of rat prolactin secretion: increased portal blood dopamine.
    Meltzer HY; Simonovic M; Gudelsky GA
    Eur J Pharmacol; 1985 Mar; 110(1):143-6. PubMed ID: 4007050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reserpine and the monoaminergic regulation of adrenal dopamine beta-hydroxylase activity.
    Lima L; Sourkes TL
    Neuroscience; 1986; 17(1):235-45. PubMed ID: 2938024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteration in L-DOPA evoked dopamine and DOPAC output under conditions of impaired vesicular dopamine storage.
    Xu K; Dluzen DE
    J Neural Transm (Vienna); 1998; 105(10-12):1091-101. PubMed ID: 9928880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for presynaptic dopamine mechanisms underlying amphetamine-conditioned locomotion.
    DiLullo SL; Martin-Iverson MT
    Brain Res; 1992 Apr; 578(1-2):161-7. PubMed ID: 1354997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents.
    Fahn S
    Adv Neurol; 1983; 37():267-76. PubMed ID: 6858776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypothalamic monoamine metabolism in mice: evaluation of drug challenges and neurotoxic insult.
    Dawson R; Callahan MF; Annau Z
    Pharmacology; 1986; 32(1):25-37. PubMed ID: 2418449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo mechanisms underlying dopamine release from rat nigrostriatal terminals: I. Studies using veratrine and ouabain.
    Fairbrother IS; Arbuthnott GW; Kelly JS; Butcher SP
    J Neurochem; 1990 Jun; 54(6):1834-43. PubMed ID: 2338544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of apomorphine, alpha-methylparatyrosine, haloperidol and reserpine on DOPA production in clonal cell lines (PC-12 and N1E-115).
    Bräutigam M; Laschinski G; Kittner B; Herken H
    Biochem Pharmacol; 1985 Apr; 34(7):941-7. PubMed ID: 3921032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.